RE: Also, the TGA has just spoken its mind on the re-packaging of a single drug for multiple individual diseases (Ibuprofen)
The TGA decision regarding Ibuprofen was based I thought on the misleading claim that particular forms of Branded Ibuprofen had extra ingredients to help them target ie back pain or headache or period pains all for an extra price. There is a difference between that which is misleading the consumer and having a product tested specifically on one disease with specific application and dosage tuned to that individual application and having trials to support. Look at the different ways asprin is rebranded. Can't agree with you here.
MSB Price at posting:
$2.33 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)